{
    "organizations": [],
    "uuid": "4abcb59d6a3f98b483221a359eea8d3089d58cff",
    "author": "",
    "url": "https://www.reuters.com/article/brief-astrazeneca-says-us-fda-approves-i/brief-astrazeneca-says-us-fda-approves-imfinzi-for-unresectable-stage-iii-non-small-cell-lung-cancer-idUSFWN1Q9017",
    "ord_in_thread": 0,
    "title": "BRIEF-AstraZeneca ‍Says US FDA Approves Imfinzi For Unresectable Stage III Non-Small Cell Lung Cancer​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 19, 2018 / 7:26 AM / in 26 minutes BRIEF-AstraZeneca ‍Says US FDA Approves Imfinzi For Unresectable Stage III Non-Small Cell Lung Cancer​ Reuters Staff Feb 19 (Reuters) - AstraZeneca Plc: * ‍US FDA APPROVES IMFINZI FOR UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER​ * ‍ASTRAZENECA‘S IMFINZI APPROVED FOR STAGE III NSCLC​ * ‍IMFINZI IS ONLY IMMUNOTHERAPY APPROVED FOR PATIENTS WITH UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER​ Source text for Eikon: Further company coverage:",
    "published": "2018-02-19T09:22:00.000+02:00",
    "crawled": "2018-02-19T09:55:31.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "minute",
        "u",
        "fda",
        "approves",
        "imfinzi",
        "unresectable",
        "stage",
        "iii",
        "cell",
        "lung",
        "reuters",
        "staff",
        "feb",
        "reuters",
        "astrazeneca",
        "plc",
        "fda",
        "approves",
        "imfinzi",
        "unresectable",
        "stage",
        "iii",
        "cell",
        "lung",
        "imfinzi",
        "approved",
        "stage",
        "iii",
        "immunotherapy",
        "approved",
        "patient",
        "unresectable",
        "stage",
        "iii",
        "cell",
        "lung",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}